Time to unshackle the medical treatment of obesity in the NHS
Authors:
Open Access
- 21 April 2024
- journal article
- research article
- Published by Elsevier in Clinical Medicine
- Vol. 24 (3) , 100206
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Semaglutide and Cardiovascular Outcomes in Obesity without DiabetesNew England Journal of Medicine, 2023
- Effect on Hemoglobin A1c (HbA1c) and Body Weight After Discontinuation of Tirzepatide, a Novel Glucose-Dependent Insulinotropic Peptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist: A Single-Center Case Series StudyCureus, 2023
- Weight Regain After Bariatric Surgery: Scope of the Problem, Causes, Prevention, and TreatmentCurrent Diabetes Reports, 2023
- Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trialNature Medicine, 2022
- Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extensionDiabetes, Obesity and Metabolism, 2022
- Adult obesity complications: challenges and clinical impactTherapeutic Advances in Endocrinology and Metabolism, 2020
- Effect of chronic liraglutide therapy and its withdrawal on time to postchallenge peak glucose in type 2 diabetesAmerican Journal of Physiology-Endocrinology and Metabolism, 2018
- 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trialThe Lancet, 2017
- Why the NHS should do more bariatric surgery; how much should we do?:BMJ, 2016
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight ManagementNew England Journal of Medicine, 2015